Dr. Hilary Cass, lead author of the independent 2024 UK review of gender-identity services for children, has stated that conducting a randomised controlled trial of puberty blockers is ethically justified to establish evidence on their risks and benefits. Dr. Cass emphasised that uncertainty about long-term safety outcomes creates a direct public health imperative to generate robust data through rigorous research.
Key takeaways
- Dr. Hilary Cass argues that a puberty blocker RCT is necessary to reduce overall harm to gender-dysphoric children by establishing evidence on safety and efficacy
- The Cass Review (2024) found insufficient evidence on long-term physical, psychological, and social outcomes of puberty suppressant therapy in minors
- Trial evidence will inform clinical decision-making for children with gender dysphoria, addressing a recognised evidence gap in current practice
🟡 Preliminary Evidence
Evidence gaps drive research imperative
According to the independent Cass Review published in 2024, which examined gender-identity services for children and young people in the UK National Health Service, the existing evidence base on puberty blockers remains limited. The review documented substantial gaps in knowledge regarding long-term physical effects, psychological outcomes, and social consequences of puberty suppression in children with gender dysphoria.
Dr. Hilary Cass, the review’s lead author, stated that the uncertainty surrounding these outcomes creates a moral and clinical imperative. In her assessment, conducting a rigorously designed randomised controlled trial represents the most ethical pathway to reduce overall harm—both by generating essential safety data and by enabling more informed clinical decision-making for individual patients.
Evidence status: Puberty blocker research domains
Cass Review (2024) assessment of evidence quality across key clinical outcomes
Source: Cass Review, Department for Health and Social Care, 2024 | Georgian Medical Journal News
Clinical uncertainty and ethical research design
The decision to conduct a puberty blocker trial reflects a fundamental principle in evidence-based medicine: when clinical uncertainty exists about a widely used intervention, prospective randomised research is often more ethical than continued prescribing without systematic outcome monitoring. According to clinical trial standards, an RCT design allows clinicians to generate reliable data on both benefit and harm simultaneously.
Dr. Cass’s position—that “more children will be harmed if we don’t do the trial than if we do”—reflects a harm-benefit calculus in which the current lack of systematic evidence itself poses a risk. Without rigorous data on long-term outcomes, clinicians and families must make treatment decisions based on incomplete information, potentially resulting in harms that could have been identified and prevented through prospective research.
The Cass Review identified insufficient evidence on long-term physical, psychological, and social outcomes of puberty suppression in children with gender dysphoria, establishing the scientific rationale for a randomised controlled trial to inform clinical practice.
— Dr. Hilary Cass, Independent Review Lead, Cass Review (2024)
Trial scope and public health implications
A puberty blocker RCT will measure multiple outcome domains across a defined patient population with diagnosed gender dysphoria. Outcomes will likely include physical safety indicators (bone density, metabolic parameters, reproductive function), psychological measures (gender dysphoria trajectory, mental health), and social functioning. These data will directly address the evidence gaps identified in the Cass Review, informing clinical guidelines and healthcare policy across the UK and internationally.
The trial also represents a commitment to the principle of evidence-based paediatric medicine. In specialty areas where clinical evidence is limited, prospective research protects patients by systematically documenting outcomes rather than relying on retrospective reports or clinical impression alone. For the gender-dysphoria population—a clinically vulnerable group with high rates of mental health comorbidity—rigorous evidence is particularly important for informed shared decision-making.
What this means
Frequently asked questions
Why is a puberty blocker trial necessary if these medications are already used clinically?
According to the Cass Review, current evidence on long-term outcomes of puberty blockers in children with gender dysphoria is insufficient for robust clinical decision-making. A randomised trial will systematically measure safety and efficacy, allowing clinicians to counsel patients on realistic risks and benefits rather than relying on incomplete data.
What outcomes will the trial measure?
Trial protocols typically assess physical safety (bone metabolism, reproductive development), psychological measures (gender dysphoria course, mental health), and social functioning. These domains directly address the evidence gaps the Cass Review identified, generating prospective data on both benefits and potential harms.
How does this trial align with evidence-based medicine principles?
Randomised controlled trials are considered the gold standard for evaluating clinical interventions when uncertainty exists. By prospectively randomising participants and monitoring outcomes systematically, an RCT provides higher-quality evidence than observational data alone, reducing bias and generating precise estimates of treatment effects.
The Cass Review’s findings have catalysed a systematic research response to resolve clinical uncertainty in a complex, high-stakes area of paediatric medicine. As the trial moves forward, it will contribute essential evidence not only to UK clinical practice but to international gender-identity service development, advancing the evidence base for informed, individualised care of children with gender dysphoria.
Source: Puberty blocker trial will help reduce harm, says Cass report author, BBC News
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
